Caladrius Biosciences Inc (CLBS)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Caladrius Biosciences Inc (CLBS) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011534
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Caladrius Biosciences Inc (Caladrius), formerly NeoStem Inc is a clinical stage development company that develops and manufactures cell therapy products. The company’s products are based on its proprietary technologies such as Dendritic Cell-Tumor Cell technology; CD34 technology; and T Regulatory technology, for immuno-oncology, ischemic repair and immunomodulation. Its developmental pipeline products include CLBS20 (NBS20) for the treatment of metastatic melanoma, CLBS10 (formerly NBS10) for ST-elevation myocardial infarction and CLBS03 for type 1 diabetes. It offers services comprising product and process development, engineering and automation, GMP manufacturing, cell and tissue processing, storage and distribution, and expert consulting and regulatory support. The company caters to biotechnology, pharmaceutical and medical product companies, and academic research institutions. It operates in Basking Ridge, Irvine and New York, the US. Caladrius is headquartered in Basking Ridge, New Jersey, the US.

Caladrius Biosciences Inc (CLBS) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Caladrius Biosciences Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Caladrius Biosciences Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Caladrius Biosciences Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Caladrius Biosciences Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Caladrius Biosciences Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Caladrius Biosciences Inc, Medical Equipment, Deal Details 11
Partnerships 11
Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 11
NeoStem Enters into Co-Development Agreement with Invetech 12
Equity Offering 13
Caladrius Biosciences Plans to Raise USD3.8 Million in Private Placement of Shares 13
NeoStem Raises USD29 Million in Public Offering of Shares 15
NeoStem to Raise USD30 Million in Private Placement of Shares 16
NeoStem Completes Public Offering Of Shares For US$40.25 Million 17
NeoStem Files Registration Statement For Private Placement Of Shares For US$8 Million 18
NeoStem Completes Public Offering Of Shares For US$11.5 Million 19
NeoStem Completes Private Placement Of Common Stock For US$3 Million 20
NeoStem Completes Public Offering Of Units For US$6.8 Million 22
NeoStem Completes An Underwritten Public Offering Of Units For US$16.5 Million 24
Acquisition 26
Hitachi Chemical Acquires Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 26
NeoStem Completes Acquisition Of California Stem Cell 28
Caladrius Biosciences Inc – Key Competitors 30
Caladrius Biosciences Inc – Key Employees 31
Caladrius Biosciences Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Nov 09, 2017: Caladrius Biosciences Reports 2017 Third Quarter Results 33
Aug 10, 2017: Caladrius Biosciences Reports 2017 Second Quarter Results 35
May 15, 2017: Caladrius Biosciences Announces 2017 First Quarter Financial Results 37
Mar 17, 2017: Caladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results 39
Nov 07, 2016: Caladrius Biosciences Reports 2016 Third Quarter Financial Results 41
Aug 09, 2016: Caladrius Biosciences Reports 2016 Second Quarter Financial Results 43
May 05, 2016: Caladrius Biosciences Reports 2016 First Quarter Financial Results 45
Mar 15, 2016: Caladrius Biosciences Announces 2015 Fourth Quarter and Full Year Financial Results 47
Corporate Communications 49
Oct 12, 2016: Caladrius Biosciences Appoints Gregory R. Brown, MD, to its Board of Directors 49
Jun 27, 2016: Caladrius Biosciences SVP and President of PCT, Robert Preti, PhD, Named Chairman of the Alliance for Regenerative Medicine 50
Product News 51
May 01, 2017: Caladrius Biosciences to Participate at Upcoming May Conferences 51
Other Significant Developments 52
Jan 06, 2016: Caladrius Tightens Strategic Focus and Provides 2016 Revenue Guidance 52
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Caladrius Biosciences Inc, Medical Equipment, Key Facts, 2016 2
Caladrius Biosciences Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Caladrius Biosciences Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Caladrius Biosciences Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Caladrius Biosciences Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Caladrius Biosciences Inc, Deals By Market, 2011 to YTD 2017 9
Caladrius Biosciences Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 11
NeoStem Enters into Co-Development Agreement with Invetech 12
Caladrius Biosciences Plans to Raise USD3.8 Million in Private Placement of Shares 13
NeoStem Raises USD29 Million in Public Offering of Shares 15
NeoStem to Raise USD30 Million in Private Placement of Shares 16
NeoStem Completes Public Offering Of Shares For US$40.25 Million 17
NeoStem Files Registration Statement For Private Placement Of Shares For US$8 Million 18
NeoStem Completes Public Offering Of Shares For US$11.5 Million 19
NeoStem Completes Private Placement Of Common Stock For US$3 Million 20
NeoStem Completes Public Offering Of Units For US$6.8 Million 22
NeoStem Completes An Underwritten Public Offering Of Units For US$16.5 Million 24
Hitachi Chemical Acquires Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 26
NeoStem Completes Acquisition Of California Stem Cell 28
Caladrius Biosciences Inc, Key Competitors 30
Caladrius Biosciences Inc, Key Employees 31
Caladrius Biosciences Inc, Other Locations 32
Caladrius Biosciences Inc, Subsidiaries 32

★海外企業調査レポート[Caladrius Biosciences Inc (CLBS)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • University of California San Diego-医療機器分野:企業M&A・提携分析
    Summary University of California San Diego (UCSD), a subsidiary of University of California, is a public research university that offers education and research with a portfolio of undergraduate, graduate, postdoctoral and professional schools. It offers courses in various fields including arts and h …
  • Straco Corporation Limited:企業の戦略・SWOT・財務情報
    Straco Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Straco Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Keyera Corp (KEY):企業の財務・戦略的SWOT分析
    Keyera Corp (KEY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Huaneng Power International Inc:発電所・企業SWOT分析
    Huaneng Power International Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on k …
  • Esperion Therapeutics Inc (ESPR):製薬・医療:M&Aディール及び事業提携情報
    Summary Esperion Therapeutics Inc (Esperion), a subsidiary of Pfizer Inc is a pharmaceutical company that develops and commercializes once-daily, oral and low-density lipoprotein cholesterol lowering therapies. The company develops oral therapies to treat patients with elevated low-density lipoprote …
  • Schneider Electric SE (SU)-エネルギー分野:企業M&A・提携分析
    Summary Schneider Electric SE (Schneider Electric), formerly Schneider Electric SA, is an energy management and automation company that develops related technologies and solutions for electricity distribution. Its product line comprises automation and control products, building management and securi …
  • Samson Oil & Gas Ltd (SSN):石油・ガス:M&Aディール及び事業提携情報
    Summary Samson Oil & Gas Limited (Samson) is engaged in the acquisition, exploitation, exploration and development of oil and natural gas properties in the US. It is also engaged in producing natural gas liquids. The company’s projects include Foreman Butte project, which is located in Williston Bas …
  • AVANGRID, Inc.:企業の戦略・SWOT・財務分析
    AVANGRID, Inc. - Strategy, SWOT and Corporate Finance Report Summary AVANGRID, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Echelon Corporation:企業の戦略的SWOT分析
    Echelon Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Dongfang Electric Corporation Ltd (1072):企業の財務・戦略的SWOT分析
    Dongfang Electric Corporation Ltd (1072) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Hal Trust:企業の戦略・SWOT・財務分析
    Hal Trust - Strategy, SWOT and Corporate Finance Report Summary Hal Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Lophius Biosciences GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Lophius Biosciences GmbH (Lophius) is a biotechnology company that develops and markets T cell-based diagnostic systems and research tools in the areas of transplantation, infectious and autoimmune diseases. The company’s T-track immunoscan assay is a test in natural or induced immune modula …
  • Methaq Takaful Insurance Company:企業の戦略・SWOT・財務情報
    Methaq Takaful Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Methaq Takaful Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • AltaGas Ltd (ALA):電力:M&Aディール及び事業提携情報
    Summary AltaGas Ltd (AltaGas) is an energy utility. The company undertakes activities related to extraction, transmission, distribution and storage of natural gas. AltaGas generates electricity utilizing diverse fuel sources, including wind, run-of-river hydro, geothermal and gas-fired generation pl …
  • Atea ASA (ATEA):企業の財務・戦略的SWOT分析
    Atea ASA (ATEA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • AS Kevelt-製薬・医療分野:企業M&A・提携分析
    Summary AS Kevelt (Kevelt), a subsidiary of Pharmsynthez is a healthcare company that develops, manufactures and markets drug products. The company offers products which include concentrate solutions for infusion, endocervical gel, eye drops and other solutions. It also offers sub-contracting and di …
  • Wintac Ltd (524758):製薬・医療:M&Aディール及び事業提携情報
    Summary Wintac Ltd (Wintac), formerly Recon Ltd is a manufacturer and marketer of sterile products. The company offers opthalmic products such as anti-glaucoma, anti-cholinergic, artificial tear, NSAID, steroids and combination, anti-infective, decongestant, anti allergic eye drops and nasal drop, a …
  • ASB Bank Limited:企業の戦略・SWOT・財務情報
    ASB Bank Limited - Strategy, SWOT and Corporate Finance Report Summary ASB Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • SM Investments Corporation (SM):企業の財務・戦略的SWOT分析
    SM Investments Corporation (SM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Warner Music Group Corp.:企業の戦略的SWOT分析
    Warner Music Group Corp. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆